Synthesis and Structure-Activity Relationship of Aminobenzophenones. A Novel Class of p38 MAP Kinase Inhibitors with High Antiinflammatory Activity

Journal of Medicinal Chemistry

Volumn 46, Issue 26, 2003, Pages 5651-5662

  Ottosen, Erik Rytter ^a   Sørensen, Morten Dahl ^a   Björkling, Fredrik ^a   Skak Nielsen, Tine ^a   Fjording, Marianne Scheel ^a   Aaes, Helle ^a   Binderup, Lise ^a  

^a LEO Pharma ^*  (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

5 (2 AMINO 4 PYRIMIDINYL) 4 (4 FLUOROPHENYL) 1 (4 PIPERIDINYL)IMIDAZOLE; 5 (2,6 DICHLOROPHENYL) 2 (2,4 DIFLUOROPHENYLTHIO)PYRIMIDO[1,6 B]PYRIDAZIN 6 ONE; 5 (4 PYRIDINYL) 4 (4 FLUOROPHENYL) 1 (4 PIPERIDINYL)IMIDAZOLE; [4 [(2 AMINOPHENYL)AMINO] 2 CHLOROPHENYL](2 METHYLPHENYL)METHANONE; [4 [(2 AMINOPHENYL)AMINO]PHENYL](PHENYL)METHANONE; AMINOBENZOPHENONE DERIVATIVE; ANTIINFLAMMATORY AGENT; BENZOPHENONE DERIVATIVE; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DERMATITIS; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; HYDROGEN BOND; IC 50; MONONUCLEAR CELL; MOUSE; NONHUMAN; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

ANILINE COMPOUNDS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BENZOPHENONES; DERMATITIS, CONTACT; FEMALE; HUMANS; INTERLEUKIN-1; INTERLEUKIN-2; LEUKOCYTES, MONONUCLEAR; LIGANDS; MICE; MICE, INBRED STRAINS; MITOGEN-ACTIVATED PROTEIN KINASES; MODELS, MOLECULAR; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PEROXIDASE; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0347627154     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm030851s     Document Type: Article

References (58)

1. Dinarello, C. A. Inflammatory cytokines: Interleukin-1 and tumor necrosis factor as effector molecules in autoimmune diseases. Curr. Opin. Imm. 1991, 3, 941-948.
2. Arend, W. P.; Dayer, J.-M. Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthitis Rheum. 1990, 33, 305-15.
3. Dayer, J. M.; Demczuk, S. Cytokines and other mediators in rheumatoid arthritis. Springer Semin. Immunopathol. 1984, 7, 387-413.
4. Barnes, P. J.; Chung, K. F.; Page, C. P. Inflammatory mediators of asthma: An update. Pharmacol. Rev. 1998, 50, 515-596.
5. Loyau, G.; Punol, J. P. The role of cytokines in the development of osteoarthritis. Scand. J. Rheumaol Suppl. 1990, 81, 8-12.
6. Kirkham, B. Interluekin-1, Immune activation pathways and different mechanisms in osteoarthitis and rheumatoid arthritis. Ann. Rheum. Dis. 1991, 50, 395-400.
7. Nickoloff, B. J. The cytokine network in psoriasis. Arch. Dermatol. 1991, 135, 1104.
8. Saklavala, J.; Davis, W.; Guesdon, F. Interleukin 1 (IL-1) and tumor necrosis factor (TNF) signal transduction. Philos. Trans. R. Soc. London B. 1996, 351, 151-157.
9. Sacca, R.; Cuff, C. A.; Ruddle, N. H. Mediators of inflammation. Curr. Opin. Imm. 1997, 9, 851-857.
10. Lewis, A. J.; Manning, A. M. New targets for antiinflammatory drugs. Curr. Opin. Chem. Biol. 1999, 3, 489-494.
11. Sekut, L.; Connolly, K. M. Pathophysiology and regulation of TNFa in inflammation. DN&P 1996, 9, 261-269.
12. Elliott, M. J.; Maini, R. N. New directions for biological therapy in rheumatoid arthritis. Int. Arch. Allergy. Immunol. 1994, 104, 112-115.
13. Moreland, L. W.; Heck, L. W., Jr.; Koopam, W. J. Biological therapy in rheumatoid arthritis: Concepts and progress. Arthritis Rheum. 1997, 40, 397-409.
14. Lee, J. C.; Kumar, S.; Griswold, D. E.; Underwood, D. C.; Votta, B. J.; Adams, J. L. Inhibition of p38 MAP kinase as a therapeutic strategy. Immunopharmacol. 2000, 47, 185-201.
15. Lee, J. C.; Laydon, J. T.; McDonnell, P. C.; Gallagher, T. F.; Kumar, S. ; Green, D.; McNulty, D.; Blumenthal, M. J.; Heys, J. R.; Landvatter, S. W.; Strickler, J. E.; McLaughlin, M. M.; Siemens, I. R.; Fisher, S. M.; Livi, G. P. ; White, J. R.; Adams, J.; Young, L.; Young, P. R. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 1994, 372, 739-746.
16. Young, P. R.; McDonnell, P.; Dunnington, D.; Hand, A.; Laydon, J.; Lee, J. C. Pyridinyl imidazoles inhibit IL-1 and TNF production at the protein level. Agents Actions 1993, 39, C67-C69.
17. Han, J.; Lee, J. D.; Bibbs, L.; Ulevitch; R. J. A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science 1994, 265, 808-811.
18. Lee, J. C.; Young, P. R. Role of CSBP/p38/RK stress response kinase in LPS and cytokine signaling mechanisms. J. Leukoc. Biol. 1996, 59, 152-157.
19. Raingeaud, J.; Whitmarsh, A. J.; Barrett, T.; Derijard, B.; Davis, R. J. MKK3- and MKK6-regulated gene expression is mediated by the p38 mitogen-activated protein kinase signal transduction pathway. Mol. Cell. Biol. 1996, 16, 1247-1255.
20. Beyaert, R.; Cuenda, A.; Vanden-Berghe, W.; Plaisance, S.; Lee, J. C.; Haegeman, G.; Cohen, P.; Fiers, W. The p38/RK mitogen-activated protein kinase pathway regulates interleukin-6 synthesis in response to tumor necrosis factor. EMBO J. 1996, 15, 1914-1923.
21. Ono, K.; Han, J. The p38 signal transduction pathway: Activation and function. Cellular Signaling 2000, 12, 1-13.
22. Herlaar, E.; Brown, Z. p38 MAPK signaling cascades in inflammatory disease. Mol. Med. Today 1999, 5, 439-447.
23. Gallagher, T. F.; Seibel, G. L.; Kassis, S.; Laydon, J. T.; Blumenthal, M. J.; Lee, J. C.; Lee, D.; Boehm, J. C.; Fier Thompson, S. M.; Abt, J. W.; Soreson, M. E.; Smietana, J. M.; Hall, R. F.; Garigipati, R. S.; Bender, P. E.; Erhard, K. F.; Krog, A. J.; Hofmann, G. A.; Sheldrake, P. L.; McDonnell, P. C.; Kumar, S.; Young, P. R.; Adams, J. L. Regulation of stress-induced cytokine production by pyridinylimidazoles; inhibition of CSBP kinase. Bioorg. Med. Chem. 1997, 5, 49-64.
24. Badger, A. M.; Bradbeer, J. N.; votta, B.; Lee, J. C.; Adams, J. L.; Griswold, D. E. Pharmacological profile of SB203580, a selective inhibitor of cytokine suppressive binding protein(p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. J. Pharm Exp. Ther. 1996, 279, 1453-1461.
25. Jackson, J. R.; Bolognese, B.; Hillegass, L.; Kassis, S.; Adams, J.; Griswold, D. E.; Winkler, J. D. Pharmacological effects of SB220025, a selective inhibitor of p38 mitogen-activated protein kinase, in angiogenesis and chronic inflammatory disease models. J. Pharmacol. Exp. Ther. 1998, 284, 687-692.
26. Hanson, G. H. Inhibitors of p38 kinase. Exp. Opin. Ther. Patents 1997, 7, 729-733.
27. Boehm, J. C.; Adams, J. L. New inhibitors of p38 kinase. Exp. Opin. Ther. Patents 2000, 10, 25-37.
28. Salituro F. G.; Germann, U. A.; Wilson, K. P.; Bemis, G. W.; Fox, T.; Su, M. S-S. Inhibitors of p38 MAP kinase: Therapeutic intervention in cytokine-mediated diseases. Curr. Med. Chem. 1999, 6, 807-823.
29. Dumas, J.; Sibley, R.; Riedl, B.; Monahan, M. K.; Lee, W.; Lowinger, T. B.; Redman, A. M.; Johnson, J. S.; Kingery-wood, J.; Scott, W. J.; Smith, R. A. ; Bobko, M.; Schoenleber, R.; Ranges, G. E.; Housley, T. J.; Bhargava, A.; Wilhelm, S. M.; Shrikhande, A. Discovery of a new class of p38 kinase inhibitors. Bioorg. Med. Chem. Lett. 2000, 10, 2047-2050.
30. Redman, A. M.; Johnson, J. S.; Dally, R.; Swartz, S.; Wild, H.; Paulsen, H.; Caringal, Y.; Gunn, D.; Renick, J.; Osterhout, M.; Kingery-Wood, J.; Smith, R. A.; Lee, W.; Dumas, J.; Wilhelm, S. M.; Housley, T. J.; Bhargava, A.; Ranges, G. E.; Shrikhande, A.; Young, D.; Bombara, M.; Scott, W. J. p38 kinase inhibitors for the treatment of arthritis and osteoporosis: Thienyl, furyl and pyrrolyl ureas. Bioorg. Med. Chem. Lett. 2001, 11, 9-12.
31. Substituted pyrazoles as p38 kinase inhibitors. Exp. Opin. Ther. Patents 1999, 9, 975-979.
32. p38 inhibitors based on the pyridylurea and pyridylacetoamide templates. Exp. Opin. Ther. Patents 2000, 10, 1151-1154.
33. Ferraccioli, G. F. VX-745 Vertex Pharmacuetical. Curr. Opin. Anti-inflam. Immunomod. Invest. Drugs 2000, 2, 74-77.
34. Pargellis, C.; Regan, J. Inhibitors if p38 mitogen-activated protein kinase for the treatment of rheumatoid arthritis. Curr. Opin. Invest. Drugs 2003, 4, 566-571
35. Pratt, J. R.; Massey, W. D.; Pinkerton, F. H.; Thames, S. F. Organosilicon compounds. XX. Sythesis of aromatic diamines via trimethylsilyl-protecting aniline intermediates. J. Org. Chem. 1975, 40, 1090-1094.
36. Weinreb, M.; Nahm, S. N-Methoxy-N-methylamides as effective acylating agents. Tetrahedron Lett. 1981, 22, 3815-3818.
37. Negishi, E.-i.; Bagheri, V.; Chatterjee, S.; Luo, F.-T.; Miller, J. A.; Stoll, A. T. Palladium-catalyzed acylation of organozincs and other organometallics as a convenient route to ketones. Tetrahedron Lett. 1983, 24, 5181-5184.
38. Evans, P. A.; Nelson, J. D.; Stanley, A. L. Directed lithiation/transmetalation approach to palladium-catalyzed cross-coupling acylation reactions. J. Org. Chem. 1995, 60, 2298-2301.
39. Bumagin, N. A.; Ponomaryov, A. B. Palladium- and nickel-catalyzed aryl- and acyl-demetalation of organometallic compounds. J. Organomet. Chem. 1985, 291, 129-132.
40. Bellamy, F. D.; Ou, K. Selective reduction of aromatic nitro compounds with stannous chloride in non acidic and non aqueous medium. Tetrahedron Lett. 1984, 25, 839-842.
41. Buchwald, S. L.; Wolfe, J. P.; Ahman, J.; Sadighi, J. P.; Singer, R. A. An ammonia equivalent for the palladium-catalyzed amination of aryl halides and triflates. Tetrahedron Lett. 1997, 38, 6367-6370.
42. Gorvin, J. H. The synthesis of di- and tri-arylamines through halogen displacement by base-activated arylamines: Comparison with the Ullmann condensation. J. Chem. Soc., Perkin Trans. 1 1988, 1331-1335.
43. Buchwald, S. L.; Wolfe, J. P. Improved functional group compatibility in the palladium-catalyzed amination of aryl bromides. Tetrahedron Lett. 1997, 38, 6359-6362.
44. Ragan, J. A.; Makowski, T. W.; Castaldi, M. J.; Hill, P. D. 2,5-Dimethylpyrrole protection facilitates cupper(I)-mediated methoxylations of aryl iodides in the presence of anilines. Synthesis 1998, 11, 1599-1603.
45. Gribble, G. W.; Kelly, W. J.; Sanford, E. Reactions of sodium borohydride in acidic media; VII. Reduction of diaryl ketones in trifluoroacetic acid. Synthesis 1978, 10, 763-765.
46. Jiang, Y.; Gram, H.; Zhao, M.; Gu, J.; Feng, L.; Padova, F. D.; Ulevitch, R. J.; Han, J. Characterization of the structure and function of the fourth member of the p38 group mitogen-activated protein kinase, p38δ. J. Biol. Chem. 1997, 272, 30122-30128.
47. Fjording, M. S. Unpublished results
48. Menéndez, M.; Laynez, J.; Medrano, F. J.; Andreu, J. M. A Thermodynamic Study of the Interaction of Tubulin with Colchicine Site Ligands. J. Biol. Chem. 1989, 264, 16367-16371.
49. Wang, Z.; Canagarajah, B. J.; Boehm, J. C.; Kassisà, S.; Cobb, M. H.; Young, P. R.; Abdel-Meguid, S.; Adams, J. L.; Goldsmith, E. J. Structural Basis of Inhibitor Selectivity in MAP Kinases. Structure 1998, 6, 117-1128
50. Wilson, K. P.; McCaffrey, P. G.; Hsiao, K.; Pazhanisamy, S.; Galullo, V. ; Bemis, G. W.; Fitzgibbon, M. J.; Caron, P. R.; Murcko, M. A.; Su, M. S. S. The Structural Basis for the Specificity of Pyridinylimidazole Inhibitors of p38 MAP Kinase. Chem. Biol. 1997, 4, 423-431.
51. Lisnock, JM.; Tebben, A.; Frantz, B.; O'Neill, E. A.; Croft, G.; O'Keefe, S. J.; Li, B.; Hacker, C.; de Laszlo, S.; Smith, A.; Libby, B.; Liverton, N.; Hermes, J.; LoGrasso, P. Molecular Basis for p38 Protein Kinase Inhibitor Specificity. Biochemistry 1998, 37, 16573-16581.
52. Liu, Y.; Bishop, A.; Witucki, L.; Kraybill, B.; Shimizu, E.; Tsien, J.; Ubersax, J.; Blethrow, J.; Morgan, D. O.; Shokat, K. M. Structural Basis for Selective Inhibition of Src Family Kinases by PP1. Chem. Biol. 1999, 6, 671-678.
53. Schindler, T.; Sicheri, F.; Pico, A.; Gazit, A.; Levitzki, A.; Kuriyan, J. Crystal Structure of Hck in Complex with a Src Family-Selective Tyrosine Kinase Inhibitor. Mol. Cell. 1999, 3, 639-648.
54. Gum, R. J.; McLaughlin, M. M.; Kumar, S.; Wang, Z.; Bower, M. J.; Lee, J. C.; Adams, J. L.; Livi, G. P.; Goldsmith, E. J.; Young, P. R. Acquisition of Sensitivity of Stress-activated Protein Kinases to the p38 Inhibitor, SB 203580, by Alteration of One or More Amino Acids within the ATP Binding Pocket. J. Biol. Chem. 1998, 273, 15605-15610.
55. Toledo, L. M.; Lydon, N. B.; Elbaum, D. The Structure-Based Design of ATP-site Directed Protein Kinase Inhibitors. Curr. Med. Chem. 1999, 6, 775-805.
56. Skak-Nielsen, T.; Tranholm, M.; Hansen, J. R. Unpublished results.
57. Grabbe, S.; Schwarts, T. Immunoregulatory mechanisms involved in elicitation of allergic contact hypersensitivity. Rev. Immunol. Today 1998, 19, 37-44.
58. Alford, J. G.; Stanley, P. L.; Todderud, G.; Tramposch, K. M. Temporal infiltration of leukocyte subsets into mice skin inflamed with phorbol ester. Agents Action 1992, 37, 260-267.